You are here: Industry Insights > NK cell

News List

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune, Successfully Produced Memory-Like NK Cells firstwordpharma
August 26, 2021
INmune Bio, Inc. (NASDAQ: INMB) announced today that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted.
ONK Therapeutics enters collaboration with blood cancer charity Anthony Nolan pharmatimes
February 23, 2021
ONK Therapeutics has announced a new collaboration with blood cancer charity Antony Nolan, with the aim of accelerating the development of next-generation natural killer (NK) cell therapies.
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy prnasia
February 22, 2021
Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
Sanofi to buy Kiadis pharmatimes
November 04, 2020
Sanofi has entered into a deal to buy Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases.